Results 41 to 50 of about 1,440 (183)

Blastic Plasmacytoid Dendritic Cell Neoplasm; A Report of Three Cases [PDF]

Iranian Journal of Medical Sciences, 2019
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematodermic myeloid malignancy that is known to be derived from plasmacytoid dendritic cells which are characterized by expression of CD4, CD56, and more specific markers such as CD123. Here,
Akbar Safaei, Ahmad Monabati, Maral Mokhtari, Freidoon Solhjoo, Mehdi Montazer   +4 more
doaj   +1 more source

Sustained response to minimal-dose tagraxofusp in a patient with BPDCN and advanced chronic kidney disease. [PDF]

Ann Hematol
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an extremely rare hematologic malignancy with an aggressive course and poor prognosis. Treatment remains challenging particularly in patients who are ineligible for stem cell transplantation due to ...
Brummer C, Evert K, Keil F, Schmidt J, Grube M, Herr W, Radsak M, Mayer S.   +7 more
europepmc   +2 more sources

An Unusual Manifestation of Blastic Plasmacytoid Dendritic Cell Neoplasm as a Testicular Tumor

Case Reports in Pathology, 2019
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a clinically aggressive hematologic malignancy arising from precursors of plasmacytoid dendritic cells that represent less than 1% of hematological malignancies.
Daniel M. Pak, Maria S. Tretiakova
doaj   +1 more source

Blastic plasmacytoid dendritic cell neoplasm of the uterus [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2020
Introduction. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and very aggressive hematological malignancy derived from precursor of the plasmacytoid dendritic cell.
Đurđević Predrag, Todorović Željko, Jovanović Danijela, Čekerevac Ivan, Novković Ljiljana, Mitrović Slobodanka, Čemerikić Vesna, Otašević Vladimir, Antić Darko   +8 more
doaj   +1 more source

Hematopoietic effects of tagraxofusp in treatment-naive patients with blastic plasmacytoid dendritic cell neoplasm. [PDF]

Cancer
Abstract Background Blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic neoplasm that expresses CD123, is often observed in the bone marrow (BM), as well as skin, blood, and viscera. Tagraxofusp, a first‐in‐class CD123‐targeted therapy, is the only drug approved to treat BPDCN.
Konopleva M, Pemmaraju N, Sweet KL, Stein AS, Rizzieri DA, Wang ES, Vasu S, Rosenblat T, Zuurman M, Gupta I, Lane AA.   +10 more
europepmc   +2 more sources

Blastic plasmacytoid dendritic cell neoplasm (BPDCN): a rare entity [PDF]

BMJ Case Reports, 2016
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive haematological malignancy in the elderly, with a high frequency of cutaneous and bone marrow involvement and poor prognosis. We report a case of BPDCN with classic presentation and discuss its treatment and the value of different investigation tools used in diagnosis and ...
Ming Sheng, Lim, Karla, Lemmert, Anoop, Enjeti   +2 more
openaire   +2 more sources

Severe tumor lysis syndrome during the induction therapy for the treatment of blastic plasmacytoid dendritic cell neoplasm arising from myelodysplastic/myeloproliferative neoplasms

Clinical Case Reports, 2021
BPDCN shows clinically heterogeneous characteristics. And as other hematological malignancies, symptoms of BPDCN suggesting a high tumor burden, such as high white blood cell count or splenomegaly, should be carefully considered to prevent TLS.
Ken Sagou, Makoto Ito, Yuma Kawamura, Shun Ukai, Miyo Goto, Nobuaki Fukushima, Kazutaka Ozeki, Ryuichi Fukuyama, Akio Kohno   +8 more
doaj   +1 more source

Blastische plasmazytoide dendritische Zellneoplasie (BPDCN)

Die Dermatologie, 2023
ZusammenfassungDie blastische plasmazytoide dendritische Zellneoplasie ist eine seltene hämatologische Neoplasie, die aus Vorläuferzellen der plasmazytoiden dendritischen Zellen entsteht und durch disseminierte, erythematöse bis bläulich-livide Plaques oder Nodi gekennzeichnet ist.
Nguyen, Katrin, Korsing, Sören, Mansour, Yasmine, Meier, Katharina   +3 more
openaire   +2 more sources

Newly-Discovered Neural Features Expand the Pathobiological Knowledge of Blastic Plasmacytoid Dendritic Cell Neoplasm [PDF]

, 2021
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and highly aggressive hematologic malignancy originating from plasmacytoid dendritic cells (pDCs).
Jessica Consiglio, Pileri, Stefano A., Gaetano Ivan Dellino, Tabanelli, Valentina, Ferracin, Manuela, Benvenuto, Giuseppe, Motta, Giovanna, Claudio Tripodo, Fanoni, Daniele, Beatrice Belmonte, Emilio Berti, Tripodo, Claudio, Berti, Emilio, Fabio Facchetti, Daniele Fanoni, Stefano A. Pileri, Federica Melle, Mazzara, Vincenzo, Fiori, Stefano, Cerroni, Lorenzo, Marcello Del Corvo, Carlo Maria Croce, Mazzara, Saveria, Saveria Mazzara, Sapienza, Maria Rosaria, Stefano Fiori, Belmonte, Beatrice, Maria Rosaria Sapienza, Giuseppe Benvenuto, Paulli, Marco, Dellino, Gaetano Ivan, Marco Paulli, Melle, Federica, Consiglio, Jessica, Fuligni, Fabio, Del Corvo, Marcello, Manuela Ferracin, Valentina Tabanelli, Sabattini, Elena, Alessandro Pileri, Croce, Carlo Maria, Vincenzo Mazzara, Pileri, Alessandro, Fabio Fuligni, Elena Sabattini, Facchetti, Fabio, Giovanna Motta, Lorenzo Cerroni   +47 more
core   +2 more sources

High ORRs Seen with Tagraxofusp-erzs in BPDCN [PDF]

Cancer Discovery, 2019
Abstract Tagraxofusp-erzs is an effective therapy for blastic plasmacytoid dendritic-cell neoplasm, according to recently published results from a multistage trial that led to the drug's 2018 approval. In the trial, the drug elicited high overall response rates, and many patients went on to receive a stem-cell transplant.
openaire   +1 more source